menu
    • menu
    [{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Preclinical","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Preclinical","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Preclinical","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kronos Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Undisclosed"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Ignota Labs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Ignota Labs","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Ignota Labs"}]

    Find Clinical Drug Pipeline Developments & Deals for 2-[4-(phenylsulfonyl)piperazin-1-yl]ethanol

    Menu

    2-[4-(phenylsulfonyl)piperazin-1-yl]ethanol

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Ignota Labs

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Ignota Labs Acquires Kronos’s Clinical Pipeline

                            Details : Under the acquisition of Istisociclib, the deal aims to advance CDK9-targeted therapy for ovarian neoplasms.

                            Product Name : KB-0742

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 06, 2025

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Ignota Labs

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kronos Bio Announces First Patient Dosed with KB-0742 in Ovarian Cancer Expansion Cohort

                            Details : KB-0742, a highly selective, orally bioavailable inhibitor of cyclin-dependent kinase 9, is being developed for the treatment of platinum-resistant high-grade serous ovarian cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 23, 2024

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Pr...

                            Details : KB-0742 is a highly selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) in development for the treatment of transcriptionally addicted solid tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 02, 2023

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reachin...

                            Details : The analysis further showed that KB-0742 continues to demonstrate a differentiated pharmacokinetic (PK) profile, with oral bioavailability and dose-proportional exposure across all four dose levels, and low to moderate variability between patients.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 07, 2022

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in...

                            Details : KB-0742 is a highly selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) and is being developed for the treatment of MYC-amplified and transcriptionally addicted solid tumors and is currently being assessed as part of an ongoing P...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 12, 2022

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potentia...

                            Details : Preclinical data featured in three posters show potential of KB-0742, a highly selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) in triple-negative breast, lung and ovarian cancers, as well as lymphoma and rare, soft-tissue can...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 08, 2022

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kronos Bio’s Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations ...

                            Details : Data include results from preclinical studies of KB-0742, orally bioavailable inhibitor of cyclin-dependent kinase 9 (CDK9) in MYC-amplified cancers, including small-cell lung, triple-negative breast and ovarian, as well as lymphoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 08, 2022

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in...

                            Details : KB-0742 is a highly selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) in development for the treatment of MYC-amplified solid tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 30, 2021

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High ...

                            Details : KB-0742 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 22, 2021

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kronos Bio Announces Publication of Preclinical Study Results for Investigational CDK9 Inhibitor KB-0742 in Ce...

                            Details : KB-0742 is a transcription regulatory network modulator discovered using the company’s proprietary high-throughput screening platform.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 22, 2020

                            Lead Product(s) : 2-(4-(Phenylsulfonyl)piperazin-1-yl)ethanol

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth